Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

The revolution is about to be televised… on Hulu. The Handmaid’s Tale has (rivetingly) been scaring the sh*t out of audiences since 2017 with frozen bank accounts, sewn-up mouths, a drowned Sydney ...

Can Gilead be held accountable for holding back the sale of an HIV drug it allegedly knew was safer than its blockbuster predecessor? The answer could offer a unique example of a situation where a ...

We recently published a list of Top 10 Stocks Wall Street is Discussing. In this article, we are going to take a look at ...

Gilead's CROI 2025 data highlights Biktarvy's sustained HIV/HBV suppression, lenacapavir's efficacy, and vesatolimod's safety ...

Harbour BioMed created Élancé Therapeutics to develop bispecific antibody drugs for weight loss. Elsewhere, Geron’s CEO is ...

A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...

Eli Lilly CEO Dave Ricks made $114 million last year, according to a new proxy statement, a rare instance of a health ...

Germany's financial markets watchdog is looking at whether Bayer fairly disclosed plans for shareholder approval of a capital ...

The company is planning a Phase 3 trial for the new formulation of lenacapavir, Stat reports. Other pharma and technology news is on microplastics and the spread of antibiotic-resistant superbugs; a ...

Marilyn Weiler treated the Monday Senior Lunch Bunch to an hour of curious and humorous bird sayings and expressions on Feb.

Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...